In the past, the age-specific incidence of most forms of cancer was widely thought to increase monotonically with age. However, cancer registry data show that the specific incidence for many forms of cancer increases with age, reaches a maximum, and then decreases. At least two hypotheses have been proposed to explain this decrease: the cell senescence hypothesis and the frailty hypothesis. The objective of our work was to formulate a stochastic model of cancer incidence to estimate the lifetime-independent odds ratio (LIOR) measuring the risk of developing a second primary cancer, conditioned on a first cancer diagnosis, relative to the risk of developing a first primary cancer, in two artificial populations: one where cancer susceptibility is universal and one where only a small proportion of individuals are born susceptible, or frail, to developing one or more cancers. The predicted LIOR values were significantly greater than 1, only
Introduction
Advancements in data quality and cataloguing have led to the observation that, in general, the incidence of many forms of cancer decreases after some age [11, 12, 19, 22] . This turnover has been observed not only in rare forms of cancer associated with younger people: bone sarcomas and testicular germ cell tumors, but also in the most common forms of cancer: prostate, colon, and breast carcinomas [3, 16, 21] . The observed turnover in cancer incidence gave rise to competing hypotheses proposing contrasting explanations for this decrease: cell senescence versus innate susceptibility. We developed a metric that measures the risk of developing a second cancer in cancer survivors, called the lifetimeindependent odds ratio (LIOR). Our objective in formulating a stochastic model to simulate the incidence of cancer in an artificial population was to compute LIOR values based on different assumptions of cancer susceptibility. Moreover, we wanted to investigate whether a one-to-one mapping between a LIOR value and the corresponding proportion of susceptibles in a population is possible.
The Cell Senescence Hypothesis
The cell senescence hypothesis states that everyone is born susceptible to developing cancer, but the age-specific cancer incidence decreases with advanced age due to the reduced potential of cell proliferation that occurs on a timescale coinciding with a typical lifespan. It is thought that this reduction in the replicative activity of somatic cells leads to a decrease in cancer incidence in individuals of an advanced age. Cells that undergo replication less frequently are less likely to experience mutations or other oncogenic events. Since carcinogenesis is a multistep process [29] that often involves mutations in oncogenes or in tumor-suppressor genes [28] , senescence acts as a tumorsuppressor mechanism by restricting cell proliferation and limiting the accumulation Lifetime-independent risk of a second primary cancer 181 of mutations [6, 14] . Senescence may be induced by DNA damage, thus preventing cells at risk of transforming into cancer cells from proliferating [4, 14] .
The reduced potential for cell proliferation of senescent cells may be a reason why cancers that occur in the oldest patients tend to be less aggressive, and are characterized by slower growth and smaller vessels compared to those that develop in the young [7, 18] . Results from animal experiments suggest that tumor suppressor mechanisms may be associated with the development of an aging phenotype characterized by reduced cell proliferation [26, 27] .
The Frailty Hypothesis
The frailty hypothesis of innate susceptibility to cancer development states that in a given population, it is possible that only a small proportion of individuals might be born frail, or susceptible, to developing cancer during a typical lifespan. This frailty is established early in life, possibly before birth, and is due to a mixture of genetic, epigenetic and environmental effects. For example, environmental factors are thought to have a major influence at the fetal stage, causing damage to the fetus and giving it an innate susceptibility, or frailty, to developing testicular cancer [1] . This hypothesis has served in the past to explain why testicular cancer primarily affects young men [25] . The lifetime risk of specific cancers increases significantly among carriers of certain susceptibility genes [8, 10] . Susceptible individuals acquire the frailty in utero or soon after birth [1, 9, 23] , are prone to an early onset of cancer, and have an increased risk of developing multiple primary cancers compared to the general population [2, 17] . It is hypothesized that susceptibles develop subsequent primary cancers due to the presence of multiple tumor precursor cells at birth.
To be clear, frailty models do not imply that a nonzero proportion of nonsusceptibles exists. In fact, a decline in average cancer incidence may be observed in a model where all individuals are susceptible, given that there is some heterogeneity in their susceptibility. In this case, individuals under greater risk will leave the population earlier in life and the set of subjects at risk will become healthier (their risk of developing cancer will be lower). However, in this computational study, we did not assume any heterogeneity of risk between individuals who are specified by the model as being susceptible. The model preassigns each individual as either being susceptible or non-susceptible, where the proportion of susceptibles is specified through one of the parameters of the model. The algorithm assigns to susceptible individuals the same probability of developing cancer during their lifetime. As frail individuals develop cancer at an earlier age than non-susceptibles, the susceptible group is reduced over time and the age-specific cancer incidence declines at advanced ages.
Materials and Methods

Modeling Approach and Implementation
We used the model to simulate the incidence of cancer in a population of one million individuals that is not subject to geographical migration. The model assumes that susceptible individuals have a cancer-prone organ or tissue consisting of a constant number of noncancerous cells, which may include healthy and tumor precursor cells. This is a plausible assumption given the fact that healthy organs tend to be in a homeostatic state, where damaged noncancerous cells are eventually destroyed via apoptosis and replaced by new healthy cells. This keeps the total number of noncancerous cells relatively constant. Once a tumor precursor cell becomes cancerous and divides clonally, the number of cancerous cells in the organ increases over time. The proliferation of cancer cells in an organ decreases the proportion of noncancerous cells, but not their number. As a simplifying assumption, the stochastic model tracks the fate of 1000 noncancerous cells, but ignores the fate of cells that have already become cancerous and of their descendants.
The model keeps track of the age of a person in years (not a cell's age) when a cell in an organ becomes the first to undergo all the necessary oncogenic events to become a cancer cell. This leads to the development and diagnosis of a first primary cancer at a particular age and calendar year. The model then records the age of each person in years when a different cell becomes the second to transform into a cancer cell, if any. This leads to the development and diagnosis of a second primary cancer. Depending on the cancer development hypothesis that is selected, it is possible for one or more cells to become cancerous or none at all. This translates into a person developing one or more primary cancers, or remaining cancer-free throughout his or her lifetime. The second cancers recorded by the model represent new second primary cancers occurring under the same probabilistic mechanisms as the first primary. In our model, second cancers do not represent recurrent or metastasized cancers or cancers that developed due to damage to healthy cells by the mode of treatment of the first cancer.
The model was coded in MATLAB (MathWorks, Natick, MA) and consists of two major for loops. The outer loop cycles over each of the individual members of the population. This outer loop is used to assign a year of birth to each person by randomly selecting a year from a linearly increasing distribution with range [1890, 2010] , such that the probability of being born in a particular year increases according to equation (1 (1) This linear increase in the birthrate allows the artificial population to exhibit a realistic increase in the number of births per year similar to the actual U.S. birth data from the 20 th century. The simulated birthrates do not have the artifact of a sudden surge in the birthrate that is present in U.S. data due to the baby boom period that took place between 1946 and 1964.
An age-specific Gompertzian-like probability of mortality that increases with age was incorporated into the model by enforcing an age-specific mortality rate of males obtained from an actuarial life table from 2009 kept by the U.S. Social Security Administration. To enforce this mortality rate, the model assigns a year of death to each person only if a specified age-dependent probabilistic condition is met. If no year of death is assigned to a person, it is assumed that he or she lived up to a maximum age of 120 years.
The simulation keeps track of the first and second primary cancer counts for the calendar years 1890 -2010, inclusive, as well as the number of individuals at risk of developing a second primary cancer, given a first cancer diagnosis, by age and calendar year. The model uses this information to compute age-specific incidence rates of first and second primary cancers per 100,000 individuals for each calendar year.
Modeling the Age-Dependent Risk of Developing Cancer
To determine the age of a person at which a cell is more likely to become cancerous, three different age-dependent functions specifying the risk of developing cancer were considered. The mathematical form of each function depends on the specific hypothesis under consideration: 1) the Armitage-Doll hypothesis of 100% susceptibility where the probability of developing cancer increases with age by following a power law, 2) the cell senescence hypothesis of 100% susceptibility where the risk of developing cancer peaks at some age and then decreases sharply thereafter due to a reduced replicative potential of senescent cells in individuals of an advanced age, and 3) the frailty hypothesis of limited susceptibility which assumes that only a small proportion of individuals are innately predisposed to develop one or more primary tumors and the rest of the population is cancer resistant. In frail individuals, the risk of developing cancer peaks at some age and then gradually decreases.
100% susceptibility is specified in the model by setting the parameter sus c to 1. To incorporate the Armitage-Doll hypothesis into the model, we used an inner for loop to cycle through each of the 1,000 noncancerous cells that make up the homeostatic organ. For each cell, the model first selects an age t in the age range [1, 120] uniformly. Then, a random number  is selected uniformly on the interval (0, 1) and its value compared to the age-specific risk function defined by the Armitage-Doll equation (2) 
where t is the age of a person in years. It can be seen from equation (2) that the larger the age t, the greater the probability that
and, therefore, the greater the probability that a cancerous tumor will develop at that age. The model assumes that a cancer is diagnosed as soon as it develops, or shortly thereafter. Once the inner loop completes the iteration process over all the 1,000 noncancerous cells, a set consisting of multiple age values is obtained. These age values are then stored and sorted. Extreme value theory is invoked by selecting the two smallest values from this set of ages, which represent the ages at which a first primary cancer and a second primary cancer were diagnosed. This procedure is repeated for each member of the population.
The cell senescence hypothesis also assumes that everyone in the population is born susceptible to developing cancer, and thus we let . A difference between the Armitage-Doll and cell senescence hypotheses is that the latter assumes that the cancer incidence turnover observed at advanced ages is due to a decreased replicative potential of cells at old age, which reduces the risk of an accumulation of oncogenic events in somatic cells. The cell senescence hypothesis predicts a risk of developing cancer that increases with age, reaches a maximum, and then rapidly decreases until the risk becomes zero after some age. To introduce this assumption, we programmed the stochastic model to first select an age t in the range [1, 120] uniformly. Then, a random number  is selected uniformly on the interval (0, 1) and its value is compared to the age-dependent value of a Beta function (3) that has previously been used to model the turnover of cancer incidence [19]   
The independent variable t represents the age of the individual in years. There is an initial power law increase, with age, of the probability of developing cancer. The probability then levels off and decreases sharply at advanced ages due to cell senescence, conferring a protection from cancer development to the oldest old. The curve takes on negative values after the age 100. Hence, the Beta function does not represent a probability density function. The probability of selecting an age t when a cancer is diagnosed depends on the age and peaks around some age interval. For very small or very large ages, the probability that
is very small. For intermediate to large age values, the probability that
is significantly large, thus increasing the probability that a cancer will develop at these ages.
The frailty hypothesis assumes that the cancer incidence turnover observed at advanced ages is due to the presence of a small proportion 1  sus c of individuals who are born susceptible to developing cancer. The rest of the population is assumed to be cancer resistant and will not develop cancer in a typical lifetime. The frailty hypothesis predicts that the probability of developing cancer increases with age, reaches a maximum, and gradually decreases at old age.
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To introduce a frailty effect in the model, a proportion , an age t in the age range [1, 120] is selected uniformly to determine the age at which the person could potentially develop cancer. Next, a random number  is selected uniformly on the interval (0, 1) and its value is then compared to a scaled Weibull distribution (4)
The variable t represents the age of the individual in years. The probability of selecting an age at which a cancer develops depends on the age. There is a range of values for which the probability that  satisfies the inequality (5)
is relatively large, increasing the likelihood that a person will develop cancer at these ages. To obtain an estimate of the parameter values to use in equations 2 through 4, we first computed preliminary parameter values by least-squares fitting a power function, a beta function and a Weibull probability density function to raw age-specific first primary breast cancer rates for females obtained from the Surveillance, Epidemiology, and End Results (SEER) network of cancer registries in the U.S. for the year 2009. Raw rates were computed by dividing the number of cancer cases in females for each age category divided by the number of females at risk of developing breast cancer at each age (see equation 6). In the end, the default values that were used in all the simulations, and that are listed in Table 1 , were values that led to sufficient first and second cancer counts for all the cancer development hypotheses, without having to consider a population consisting of tens of millions of individuals. These parameter values also ensured that not everyone in the population actually develops cancer during their lifetime, thus keeping the simulated incidence rates realistic. Based on a sensitivity analysis, the LIOR values presented in the results section were robust with respect to slight variations in the default parameter values. 
Proportion of Cancer Diagnoses Based on Distinct Risk Functions
Each of the three functions prescribing the risk of cancer development was incorporated into the model one at a time. Cancer development was either an inevitable outcome of aging, or a rare event, depending on which cancer development hypothesis was considered. Hence, we first selected one of the agedependent cancer risk functions (Power Law, Beta or Weibull) and then considered a constant number of noncancerous cells that the organ consists of. Depending on the risk function that was selected, a population consisting of at least one million people was required in order to obtain sufficient second cancer counts. It was important to obtain a sufficiently large number of first and second cancer counts in order to reduce the random error and uncertainty in the incidence rates, which affect the estimation of the lifetime-independent odds ratios. Once a fixed number of cells and the age-specific probability of transformation into a cancer cell were specified, the proportion of individuals of the entire population diagnosed with a first and a second primary cancer was pre-determined.
The proportion of individuals diagnosed with cancer was robust with respect to the initial size of the population. That is, once the number of noncancerous cells and the age-dependent risk of transformation into a cancer cell were specified, the proportion of the population that was eventually diagnosed with a first and a second cancer remained relatively constant for a wide range of initial population sizes ranging from thousands to millions of individuals.
Derivation of a LIOR Value
Although the derivation of the model, and the assumptions made to compute a LIOR value, could have followed principles used in survival analysis and age-period-cohort models, our intent was to approximate the probability of a person developing cancer at a particular age by considering the total number of cancer counts at a particular age, and the pool of individuals at risk of developing cancer at that age. Formally, in a continuous model characterized by a hazard function, the probability of developing cancer at any particular age is always zero.
Lifetime-independent risk of a second primary cancer
187
In our discrete formulation, however, we assumed that the raw incidence rate defined by (6) 
had not yet been diagnosed with a first primary cancer and were still alive in the selected year. Hence, these individuals were at risk of developing a first cancer of the specified type. The agespecific cancer counts and the age-specific populations at risk were assumed to follow a Poisson process [5] . Since a cancer incidence rate at age i is a quotient of two Poisson variables (i.e., cancer counts and number of individuals at risk of developing cancer at age i ), by error analysis theory [24] the "Poisson uncertainty" of an age-specific cancer rate is r , decreases as the first cancer counts and/or the number of susceptibles increases. In general, the number of individuals at risk of developing cancer is large. Hence, the main source of uncertainty of an incidence rate at a particular age is usually due to the relatively low number of first primary cancer counts at that age.
Considering aggregated data for multiple years increases the number of age-specific cancer cases and the size of the populations at risk of developing cancer, which reduces the Poisson uncertainty and leads to smoother age-specific cancer incidence curves. Therefore, to reduce the uncertainty of the simulated data and of the computed LIOR values, we considered aggregated data for the years 2000 -2009 in all our analyses. It is valid to use aggregated data generated by the stochastic model from multiple years because no cohort effects, nor time varying trends in cancer incidence, were introduced into the model. The probability of developing a first primary cancer at age i , based on data from the years 2000 to 2009, is given by equation ( represents the probability of not developing a first cancer at age i . We used the lifetime-independent probability f r to compute the lifetimeindependent odds of developing a first primary cancer
. By a similar process, we obtained the lifetime-independent odds of developing a second primary cancer s  , conditioned on a first cancer diagnosis, from agespecific second cancer incidence data. We defined the lifetime-independent odds ratio as which quantifies the risk of someone in the population developing a second primary cancer, given that he or she has already been diagnosed with a first primary cancer diagnosis, relative to the risk that someone in the population who has not been diagnosed with cancer develops a first primary cancer during his or her lifetime.
Results
Cancer Incidence Rates Predicted by the Simulation
For the Armitage-Doll assumption, Figure 1 shows the first primary cancer counts, the age-specific number of individuals who had not yet been diagnosed with a first primary cancer and who were at risk of developing a first cancer during the years 2000 -2009, and the age-specific incidence rates of a first primary cancer per 100,000 individuals. These results correspond to the case when 88% of the members of a population consisting of one million individuals were diagnosed with a first primary cancer and 33% were diagnosed with a second primary cancer during the years 1890 -2010. It is worth noting that an assumption of 100% susceptibility does not mean that everyone in the population will actually develop cancer. 100% susceptibility means that everyone in the population has a risk of developing cancer in a typical lifetime, but it is also possible for susceptible individuals to remain free of cancer. The level of susceptibility of an individual person depends on the chosen values of the model parameters, including the number of cells that the cancer-prone organ consists of. Figure 2 shows the corresponding second primary cancer incidence data when the Armitage-Doll hypothesis was considered. The figure shows the second primary cancer counts, the age-specific number of individuals who had been diagnosed with a first primary cancer but had not yet been diagnosed with a second primary cancer during 2000 -2009, and the age-specific incidence rates of a second primary cancer per 100,000 individuals. As expected, the first and second cancer incidence rates predicted by the simulation increase with age by following a power law. Figure 3 shows the results for first primary cancers obtained by considering the cell senescence hypothesis. The percentages of first and second cancer cases out of a population of one million individuals were 9.7% and 0.4%, respectively. As expected, the first cancer incidence rates initially increase with age, reach a peak and then rapidly decrease at advanced ages. A B C Figure 4 shows the results for second cancers. Again, the second cancer rates increase with age, attain a maximum and then decrease. This cancer incidence turnover is expected whenever cell senescence acts to reduce the proliferation of somatic cells in the oldest old, conferring them with a resistance to developing cancer. Lastly, a frailty effect was incorporated by specifying the percent of susceptibles to developing cancer to be 10% of the entire population. The agespecific incidence rates of a first primary cancer are shown in Figure 5 . The percentages of first and second cancer diagnoses were 5.7% and 2%, respectively. The plots of the first cancer counts, the age-specific populations at risk of developing a first cancer, and the incidence rates are similar to those obtained when a cell senescence effect was assumed. A key difference between the frailty and cell senescence hypotheses is that cancer incidence decreases more gradually when a Weibull function is used instead of a Beta function. Figure 6 shows the incidence rates for second primary cancers. Table 2 shows the LIOR values, based on the Armitage-Doll hypothesis, as a function of the number of cells that make up the cancer-prone organ. For this cancer risk assumption, the LIOR values predicted by the model were significantly less than 1, as evidenced by the 95% confidence intervals. Please refer to the appendix for the derivation of the confidence intervals. The Armitage-Doll assumption led to a lifetime-independent probability of developing a second primary cancer s r that was smaller than the lifetimeindependent probability of developing a first primary cancer f r . This difference in the probabilities explains why the LIOR values that were obtained under this hypothesis were significantly less than 1. The likelihood of being diagnosed with a second cancer, given a first diagnosis, did not increase. We obtained LIOR values approximately equal to 1 under the Armitage-Doll hypothesis only when the Gompertzian age-specific mortality rates were not enforced. These results suggest that a LIOR value significantly less than 1 is to be expected if the risk of developing cancer and the mortality rate both increase with age. Table 3 shows the predicted LIOR values as a function of the number of cells that make up the cancer-prone organ based on a cell senescence assumption. In this case, the LIOR values were not significantly different from 1. This result suggests that, although cell senescence acts to reduce the likelihood of developing cancer at advanced ages, it does not decrease significantly the overall lifetimeindependent probability of developing a subsequent cancer in cancer survivors. Lastly, we introduced a frailty effect, while excluding the other two hypotheses of cancer development. Table 4 shows the predicted LIOR values as a function of the number of cells that make up the organ. To simulate an innate frailty in the population, we specified 10% of the population to be susceptible to cancer by letting
Lifetime-Independent Odds Ratios Predicted by the Simulation
. In this case, the LIOR values were significantly greater than 1, and the lifetime-independent probability of developing a second primary cancer s r was approximately ten times greater than the lifetime-independent probability of developing a first primary cancer f r . ) of individuals in the artificial population were born susceptible to developing cancer. The LIOR curve generated from the stochastic model sheds light on the possibility that a LIOR value computed from actual cancer registry data, such as that maintained by SEER, can potentially serve as a metric to estimate the proportion of susceptibles to a particular type of cancer in the U.S. population. of individuals born susceptible to developing cancer. When 100% susceptibility was assumed in the model, the predicted LIOR value was approximately equal to 0.9 and it increased when a smaller proportion of susceptibles was specified.
Discussion
Our computational work shows that in an artificial population where a limited number of individuals are susceptible to developing cancer, the LIOR value will be significantly greater than 1. In such a population, the risk of susceptible individuals of developing a second primary cancer, given that they have already been diagnosed with a first cancer, is greater than the risk of developing a first cancer. This outcome is based on how the probability of developing a cancer is specified in the model if someone is selected, with a given probability, to be a susceptible. In a human population, the increased probability of developing a second cancer may be due to the fact that many cancer survivors have an innate predisposition to developing multiple primary cancers. This susceptibility, or frailty, to developing cancer is often conferred by genetic or epi- ) and polymorphisms in low penetrance genes [13, 15, 20] . The proportion of susceptibles to cancer development in the general population is not yet well known, since cancer incidence varies to a great extent when geographical region is taken into account.
A motivation for deriving a model of cancer incidence in a synthetic population to compute LIOR values is that even actual cancer incidence data of the highest quality may contain a certain level of overreporting or underreporting bias. For example, individuals in a region under surveillance by SEER are monitored more closely, which increases the likelihood of a cancer diagnosis once it develops. Underreporting may occur due to migration of individuals out of a region under surveillance or a primary cancer misclassification. Moreover, the treatment used to eliminate the first cancer may affect the age-specific second cancer rates. These sources of bias were eliminated in our computational analysis.
Although a month-by-month account of the population dynamics would have made the model simulation more realistic, it would not have affected the overall results. Thus, to keep the code tractable and the simulation time reasonable, the model did not consider births, deaths or cancer diagnoses on a month-by-month basis. Neither did the model consider a continuous birth process of new individuals into the population nor migration into or out of the population. Although generating such detailed data would have made the artificial data more realistic, this added realism would have increased the computational and timewise cost even further.
Some aspects of the human population are challenging to simulate, including the interaction of multiple diseases and how they affect survival and cancer incidence. The chances of survival after the onset of cancer may be substantially lower, depending on the type of cancer and the treatment options that are available. Moreover, changes in personal lifestyle that reduce the likelihood of developing cancer are not easy to simulate in silico. More advanced algorithms will be required to implement the essential behavioral and psychological characteristics of the members of a population and how they affect disease progression and regression.
Even when considering a population of one million people, some of the age-specific second cancer incidence curves generated by the model were not as smooth as desired due to low second cancer counts for certain ages. In order to obtain a larger number of cancer counts, the simulation can be run by considering a much larger initial population consisting of tens of millions of individuals. It is expected that a larger population size will reduce the propagation of error, which will lead to a better estimate of the age-specific cancer incidence rates and the LIOR values. Running the program with these new assumptions will require rewriting the MATLAB code to take advantage of parallel programming. Another option is to use cloud computing to take advantage of the faster computing resources that are available commercially.
An alternative approach to make the computation of LIOR values robust to the presence of data points that have high uncertainty would be to implement a method involving weighted least squares regression to fit smooth curves through the first and second cancer rate data points. The 95% confidence curves that would be generated could then be used to estimate LIOR values and their 95% confidence intervals.
The model did not make a distinction between two cancer diagnoses in different anatomical sites. That is to say, the model did not take into account the differences in the required number and type of genetic or epigenetic changes that are required for a cancer in different organs to develop. The model was formulated with the assumption that the first and second cancers developed in the same site. The predictions of the model can be made more realistic by introducing programming algorithms to make it possible to simulate the incidence of a first primary cancer in a particular organ, and a subsequent cancer in the same or a different site. This will require taking into account the key biological aspects of the carcinogenesis process that are specific to each type of cancer.
A validation of the model with actual cancer registry data would need to be performed before a LIOR curve derived from the model could be used to map a SEER-derived LIOR value to a proportion of susceptibles. There is a high variability in the age-specific cancer rates among populations living in different geographical regions and between cancer types. The availability and quality of cancer incidence data also varies from country to country. Consequently, the possibility of constructing a LIOR curve that is population-specific is yet to be determined.
The key advantage of using LIOR values is that they are simple to compute and interpret because they are derived directly from the lifetimeindependent probabilities f r and s r of developing a first and second primary cancer, respectively. The direct connection to the probabilities of developing a first and a second cancer makes LIOR values useful as a metric of relative risk. In a human population, LIOR values obtained from cancer registry data can also be used to assess the relative likelihood of developing a subsequent primary cancer of the same type as the first cancer, between individuals who were diagnosed with different types of first primary cancers by computing the ratio of two LIOR values.
Conclusion
The stochastic model predicted a LIOR value significantly greater than 1 only when a frailty effect was introduced as part of the model assumptions. A value not significantly different from 1 was obtained when we assumed that the susceptibility to developing cancer is universal (the Armitage-Doll and cell senescence hypotheses). These results suggests that if a frailty effect were to exist in the U.S. population, such as a small proportion of individuals who are born susceptible to developing colon cancer, it would be reflected in a LIOR value that is significantly greater than 1; the exact value would depend on the proportion of susceptibles. Therefore, in addition to serving as a measure of relative risk, a LIOR value can potentially be used to indirectly estimate the proportion of individuals who are born susceptible to developing a particular type of cancer. Being able to determine the proportion of susceptibles in a population from a LIOR value would have major health policy implications, as it would spur further interest in developing a diagnostic tool to determine the demographics of at-risk individuals. Once identified, these individuals would be monitored closely and recommended for preventive care, including medical intervention and/or lifestyle change advice long before any symptoms begin to appear.
